Minerva Neurosciences (NASDAQ:NERV – Get Free Report) and Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.
Institutional and Insider Ownership
34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 10.4% of Minerva Neurosciences shares are held by company insiders. Comparatively, 4.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Minerva Neurosciences and Ernexa Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Minerva Neurosciences | N/A | N/A | -$293.42 million | ($26.80) | -0.22 |
| Ernexa Therapeutics | $580,000.00 | 10.16 | -$14.08 million | ($3.02) | -0.07 |
Ernexa Therapeutics has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Minerva Neurosciences has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 6.79, suggesting that its share price is 579% more volatile than the S&P 500.
Profitability
This table compares Minerva Neurosciences and Ernexa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Minerva Neurosciences | N/A | N/A | -35.62% |
| Ernexa Therapeutics | N/A | -1,262.77% | -228.54% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Minerva Neurosciences and Ernexa Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Minerva Neurosciences | 1 | 1 | 0 | 0 | 1.50 |
| Ernexa Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Minerva Neurosciences presently has a consensus target price of $7.00, suggesting a potential upside of 19.25%. Given Minerva Neurosciences’ stronger consensus rating and higher possible upside, research analysts plainly believe Minerva Neurosciences is more favorable than Ernexa Therapeutics.
Summary
Ernexa Therapeutics beats Minerva Neurosciences on 6 of the 11 factors compared between the two stocks.
About Minerva Neurosciences
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
